title: Cord blood banking and transplantation at the Mexican Institute of Social Security: the first 5 years.
abstract: BACKGROUND
  In January 2005, the Cord Blood Bank (CBB) at the Mexican Institute of Social Security initiated activities. Herein, we describe the experience generated during this period (January 1, 2005-December 31, 2009).
  
  
  METHODS
  Good manufacturing practices and standard operating procedures were used to address donor selection, as well as umbilical cord blood (UCB) collection, processing, and cryopreservation. Based mainly on HLA and nucleated cell content, specific UCB units were thawed, processed, and released for transplantation.
  
  
  RESULTS
  A total of 589 UCB units were stored, representing 54% of the total number of units collected. Forty-eight units (8.14% of the stored units) were released for transplantation of 36 patients. Twenty-six patients (72% of cases) corresponded to patients with acute leukemia, five (14%) to patients with marrow failure, and the rest (five; 14%) to patients with hemoglobinopathies and other syndromes. The median number of nucleated cells infused per patient was 6.71 × 10(7) /kg and the median number of CD34+ cells was 4.8 × 10(5) /kg. Current engraftment data indicate that engraftment occurred in 56%, and no engraftment in 44%, of cases. Engraftment was more frequent (59%) in patients that received more than 3 × 10(7) total nucleated cells (TNCs)/kg body weight, than in those receiving fewer than 3 × 10(7) TNCs/kg (40%). Myeloid engraftment was observed 7 to 54 days posttransplant (median, 23 days), whereas platelet engraftment was detected on Days 12 to 87 posttransplant (median, 38 days). To date, the disease-free survival rate was 41% and the overall survival was 47%, with survival periods of 126 to 1654 days.
  
  
  CONCLUSIONS
  Although the experience presented herein is still limited and the period of analysis is still short, the results obtained during these 5 years are encouraging.
authors.affiliation: Umbilical Cord Blood Bank and Department of Pediatric Hematology, La Raza Medical Center, Mexican Institute of Social Security, Mexico City, Mexico.
authors.forename: Angel
authors.initials: A
authors.lastname: Guerra-Marquez
authors.forename: Barbara
authors.initials: B
authors.lastname: Novelo-Garza
authors.forename: Araceli
authors.initials: A
authors.lastname: Malagón-Martínez
authors.forename: Alejandro
authors.initials: A
authors.lastname: Limon-Flores
authors.forename: Fernando
authors.initials: F
authors.lastname: Luna-Bautista
authors.forename: Luis
authors.initials: L
authors.lastname: Juan-Shum
authors.forename: Ines
authors.initials: I
authors.lastname: Montero-Ponce
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Sanchez-Valle
authors.forename: Karina
authors.initials: K
authors.lastname: Peñaflor
authors.forename: Maria Antonieta
authors.initials: MA
authors.lastname: Vélez-Ruelas
authors.forename: Yanin
authors.initials: Y
authors.lastname: Romero-Juárez
authors.forename: Hector
authors.initials: H
authors.lastname: Mayani
mesh_terms: D000741:Anemia, Aplastic / Q000628:therapy; D001771:Blood Banks / Q000706:statistics & numerical data*; D001772:Blood Cell Count; D002467:Cell Nucleus; D036101:Cord Blood Stem Cell Transplantation / Q000706:statistics & numerical data*; D018572:Disease-Free Survival; D005312:Fetal Blood; D006085:Graft Survival; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000648:ultrastructure; D006453:Hemoglobinopathies / Q000628:therapy; D006801:Humans; D007231:Infant, Newborn; D007938:Leukemia / Q000628:therapy; D008800:Mexico; D012189:Retrospective Studies; D012943:Social Security; D016896:Treatment Outcome